Pharmaceutical care for patients with G6PD deficiency




Glucosephosphate dehydrogenase deficiency; Signals and symptons; Pharmaceutical care; Therapy.


Historically, G6PD deficiency was reported for the first time in individuals who received doses of primaquine, the primary drug to be addressed in the study, to treat malaria, and triggered a symptomatic response with jaundice and a hematological field of erythroenzymopathies. In this sense, through an integrative review, the present research aimed to discuss the importance of pharmaceutical care and its relationship with the treatment of patients with G6DP enzyme deficiency. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzyme deficiency prevalent in many malaria-endemic countries. In this sense, patients with G6PD deficiency are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain drugs, including 8-aminoquinolines used to treat Plasmodium vivax malaria. In this way, pharmaceutical care would become a tool for monitoring patients and managing problems that may occur during pharmacotherapy. Guiding, educating and implementing quantitative mechanisms for diagnosing and providing adequate radical cure in heterozygous women, who remain at risk of hemolysis.


Bernardo, J., & Nock, M. (2015). Pediatric provider insight into newborn screening for glucose-6-phosphate dehydrogenase deficiency. Clinical pediatrics, 54(6), 575-578.

Brito-Sousa, J. D., Murta, F., Vitor-Silva, S., Sampaio, V. S., Mendes, M. O., Brito, M. A., & Lacerda, M. V. (2021). Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study). PLoS neglected tropical diseases, 15(5), e0009415.

Cappellini, M. D., & Fiorelli, G. E. M. I. N. O. (2008). Glucose-6-phosphate dehydrogenase deficiency. The lancet, 371(9606), 64-74.

Carter, A. J., Aggarwal, M., Kopia, G. A., Tio, F., Tsao, P. S., Kolata, R., & Falotico, R. (2004). Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovascular research, 63(4), 617-624.

Dysoley, L., Kim, S., Lopes, S., Khim, N., Bjorges, S., Top, S., & Taylor, W. R. (2019). The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC infectious diseases, 19(1), 1-11.

Eziefula, A. C., Pett, H., Grignard, L., Opus, S., Kiggundu, M., Kamya, M. R., & Drakeley, C. (2014). Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine. Antimicrobial agents and chemotherapy, 58(8), 4971-4973.

Fanello, C. I., Karema, C., Avellino, P., Bancone, G., Uwimana, A., Lee, S. J., & Modiano, D. (2008). High risk of severe anaemia after chlorproguanil-dapsone+ artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PloS one, 3(12), e4031.

Gerth-Guyette, E., Adissu, W., Brito, M., Garbin, E., Macedo, M., Sharma, A., & Domingo, G. J. (2021). Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation. Malaria Journal, 20(1), 1-11.

Iglessias, M. A. C., Santos, R. M. V., Amorim, M. D. S. T., Silva, R. T., Moreira, S. S., Barretto, O. C., & Medeiros, T. M. D. (2010). Deficiência de glicose-6-fosfato desidrogenase eritrocitária em recém-nascidos do sexo masculino e sua relação com a icterícia neonatal. Revista Brasileira de Hematologia e Hemoterapia, 32(6), 434-438.

Luzzatto, L., Nannelli, C., & Notaro, R. (2016). Glucose-6-phosphate dehydrogenase deficiency. Hematology/Oncology Clinics, 30(2), 373-393.

Meloni, T. (1995). Haemoglobinuria and haptoglobin in g 6pd deficiency. British Journal of Haematology, 91, 511-520.

Mendes, K. D. S., Silveira, R. C. D. C. P., & Galvão, C. M. (2019). Uso de gerenciador de referências bibliográficas na seleção dos estudos primários em revisão integrativa. Texto & Contexto-Enfermagem, 28, e20170204.

Maillart, E., Leemans, S., Van Noten, H., Vandergraesen, T., Mahadeb, B., Salaouatchi, M. T., & Clevenbergh, P. (2020). A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infectious Diseases, 52(9), 659-661.

Martins, S. E. S., & Martins, E. S. (2018). As especificidades no diagnóstico de enfermagem ao paciente portador da deficiência G6PD. Revista Saúde-UNG-Ser, 11(1 ESP), 12.

Müller, O., Mockenhaupt, F. P., Marks, B., Meissner, P., Coulibaly, B., Kuhnert, R., & Mansmann, U. (2013). Haemolysis risk in methylene blue treatment of G6PD‐sufficient and G6PD‐deficient West‐African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiology and drug safety, 22(4), 376-385.

Nkhoma, E. T., Poole, C., Vannappagari, V., Hall, S. A., & Beutler, E. (2009). The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells, Molecules, and Diseases, 42(3), 267-278.

Oo, N. N., Bancone, G., Maw, L. Z., Chowwiwat, N., Bansil, P., Domingo, G. J., & Nosten, F. (2016). Validation of G6PD point-of-care tests among healthy volunteers in Yangon, Myanmar. PloS one, 11(4), e0152304.

Poirot, E., Vittinghoff, E., Ishengoma, D., Alifrangis, M., Carneiro, I., Hashim, R., & Gosling, R. (2015). Risks of hemolysis in glucose-6-phosphate dehydrogenase deficient infants exposed to chlorproguanil-dapsone, mefloquine and sulfadoxine-pyrimethamine as part of intermittent presumptive treatment of malaria in infants. PloS one, 10(11), e0142414.

Wojnarski, B., Lon, C., Sea, D., Sok, S., Sriwichai, S., Chann, S., & Wojnarski, M. (2020). Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia. PLoS One, 15(1), e0228207.

Zobrist, S., Brito, M., Garbin, E., Monteiro, W. M., Clementino Freitas, S., Macedo, M., & Lacerda, M. V. (2021). Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil. PLoS neglected tropical diseases, 15(8), e0009649.



How to Cite

CORDEIRO, J. M. da S. .; CORREIA, B. I. da S. G. .; GUEDES, J. P. de M. . Pharmaceutical care for patients with G6PD deficiency. Research, Society and Development, [S. l.], v. 11, n. 14, p. e559111436752, 2022. DOI: 10.33448/rsd-v11i14.36752. Disponível em: Acesso em: 9 dec. 2022.



Review Article